New oral drug could tame overactive bone marrow in rare blood cancers
NCT ID NCT07626021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a pill called selinexor in 15 adults with chronic blood cancers (MPN) whose blood cell counts are too high. The goal is to see if selinexor can safely bring those counts down and ease symptoms. Participants take the drug once a week for up to 3 months and are followed for 6 months total.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selinexor (KPT-330), an oral drug that blocks a protein to help control cancer cell growth
- What this could lead to
- If it works, selinexor could offer a new oral option for patients with certain blood cancers who need to lower their blood cell counts but have few other choices.
- What could go wrong
- This is a very small, early-phase trial with only 15 people, so results may not apply widely. The drug can cause side effects like low blood counts or other toxicities, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a hormone mimic curb the need for bloodletting in a blood cancer?
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new pill shrink the spleen in myelofibrosis?
- Can a daily pill shrink the spleen in myelofibrosis?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Can a new drug reduce bloodletting for polycythemia vera?